Table 1:
Results of univariate analysis for predictors of AIS in clinical Stage IA lung cancer patients with a part-solid nodule
| Clinical factors | No. of patients | No. of patients with AIS (%) | P-value* |
|---|---|---|---|
| Total | 112 | 13 (12) | |
| Gender | |||
| Male | 41 | 3 (7) | 0.28 |
| Female | 71 | 10 (14) | |
| Age (years) | |||
| ≥70 | 33 | 2 (6) | 0.24 |
| <70 | 79 | 11 (14) | |
| Pack-year smoking | |||
| ≥20 | 26 | 2 (8) | 0.48 |
| <20 | 86 | 11 (13) | |
| Clinical T-status | |||
| c-T1a | 66 | 12 (18) | <0.01 |
| c-T1b | 46 | 1 (2) | |
| Pleural involvement | |||
| Absent | 59 | 9 (15) | 0.20 |
| Present | 53 | 4 (8) | |
| Air bronchogram | |||
| Absent | 30 | 6 (20) | 0.09 |
| Present | 82 | 7 (9) | |
| Preceding malignancies | |||
| Absent | 101 | 10 (10) | 0.09 |
| Present | 11 | 3 (27) | |
| CEA | |||
| ≤3 | 77 | 9 (12) | 0.97 |
| >3 | 35 | 4 (11) | |
| CTR | |||
| ≤0.35 | 13 | 3 (23) | 0.16 |
| >0.35 | 99 | 10 (10) | |
| ≤0.40 | 26 | 7 (27) | <0.01 |
| >0.40 | 86 | 6 (7) | |
| ≤0.45 | 33 | 9 (27) | <0.01 |
| >0.45 | 79 | 4 (5) | |
| SUVmax | |||
| ≤1.0 | 43 | 9 (21) | 0.02 |
| >1.0 | 69 | 4 (6) | |
| ≤1.5 | 63 | 11 (17) | 0.03 |
| >1.5 | 49 | 2 (4) | |
| ≤2.0 | 81 | 13 (16) | 0.02 |
| >2.0 | 31 | 0 (0) | |
AIS: adenocarcinoma in situ; CEA: carcinoembryonic antigen; CTR: consolidation/tumour ratio; SUV: standardized uptake value.
*P-value in χ2 test or Fisher's exact test.